Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)–a comparison between 2004-2006 and 2007-2009

BMC Cancer

Nobumichi Tanaka¹  Akihide Hirayama¹  Tatsuo Yoneda¹  Katsunori Yoshida¹  Keiji Shimada²  Noboru Konishi²  Kiyohide Fujimoto¹ 

[1] Department of Urology, Nara Medical University, Nara, Japan

[2] Department of Pathology, Nara Medical University, Nara, Japan

关键词: Active surveillance;    Risk classification;    Radiation therapy;    Radical prostatectomy;    Primary androgen deprivation therapy;    Primary therapy;   

Others  :  859205
DOI  :  10.1186/1471-2407-13-588

 received in 2013-04-04, accepted in 2013-12-04,  发布年份 2013

【 摘 要 】

Background

To assess the trends of risk classification and primary therapy in Japanese patients who were diagnosed with prostate cancer between 2004-2006 and 2007-2009.

Methods

A total of 4752 patients who were newly diagnosed with prostate cancer at Nara Medical University and its 23 affiliated hospitals between 2004 and 2009 were enrolled. The differences in risk classification and primary therapy were compared in patients who were newly diagnosed between 2004-2006 (prior period) and 2007-2009 (latter period).

Results

The proportion of patients with a high or greater risk significantly decreased in the latter period compared to the prior period (p < 0.001). The proportion of primary androgen deprivation therapy (PADT) was 50% in the prior period, and 40% in the latter period. On the other hand, the proportion of radiation therapy was 14% in the prior period, but 24% in the latter period. The proportion of radical prostatectomy was the same in the two periods (30%). The primary therapy was significantly different between the two periods (p < 0.001).

Conclusions

Higher risk patients significantly decreased in the latter period compared to the prior period. The use of PADT also significantly decreased in the latter period. However, there were still higher risk patients in Japan, and the use of PADT was still common in patients with localized prostate cancer or locally advanced prostate cancer in Japan.

【 授权许可】

   
2013 Tanaka et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Tanaka N, Fujimoto K, Hirayama A, Yoneda T, Yoshida K, Hirao Y: Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data. Jpn J Clin Oncol 2010, 40:588-592.
• [2]Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR: CaPSURE: time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003, 170:S21-S27.
• [3]Cancer Registration Committee of the Japanese Urological Association: Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 2005, 12:46-61.
• [4]Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Namiki M, Hirao Y, Murai M, Yamanaka H: Japan study group of prostate cancer (J-CaP): current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol 2007, 37:775-781.
• [5]D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
• [6]Fujimoto H, Nakanishi H, Miki T, Kubota Y, Takahashi S, Suzuki K, Kanayama HO, Mikami K, Homma Y: Oncological outcomes of the prostate cancer patients registered in 2004: report from the cancer registration committee of the JUA. Int J Urol 2011, 18:876-881.
• [7]Cooperberg M, Lubeck DP, Penson D, Mehta SS, Carroll PR, Kane CJ: Sociodemographic and clinical risk characteristics of patients with prostate cancer within the veterans affairs health care system: data from CaPSURE. J Urol 2003, 170:905-908.
• [8]Cooperberg MR, Broering JM, Kantoff PW, Carroll PR: Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007, 178:S14-S19.
• [9]Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, Grading ISUP: Committee: the international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 2005, 2005(29):1228-1242.
• [10]Cooperberg MR, Cowan J, Broering JM, Carroll PR: High-risk prostate cancer in the United States, 1990-2007. World J Urol 2008, 26:211-218.
• [11]Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR, Akaza H: Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 2009, 27:4306-4313.
• [12]Ito K, Kakehi Y, Naito S, Okuyama A, Japanese Urological Association: Japanese urological association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan. Int J Urol 2008, 15:763-768.
• [13]Sirovich BE, Schwartz LM, Woloshin S: Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 2003, 289:1414-1420.
• [14]Tanaka N, Fujimoto K, Hirayama A, Samma S, Momose H, Kaneko Y, Haramoto M, Hayashi Y, Nakagawa Y, Otani T, Watanabe S, Hirao Y: The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara uro-oncological research group registration. BMC Urol 2011, 11:6. BioMed Central Full Text
• [15]Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, Pollack A: Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer: who dies of disease? Int J Radiat Oncol Biol Phys 2011, 79:1310-1317.
• [16]Stone NN, Stone MM, Rosenstein BS, Unger P, Stock RG: Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol 2011, 185:495-500.